Nomura Asset Management Co. Ltd. Has $26.92 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Nomura Asset Management Co. Ltd. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 65,121 shares of the company’s stock after selling 343 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $26,924,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Cranbrook Wealth Management LLC boosted its holdings in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock valued at $158,000 after acquiring an additional 25 shares during the last quarter. Perigon Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 1.8% in the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock valued at $632,000 after purchasing an additional 26 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock valued at $335,000 after purchasing an additional 26 shares during the last quarter. IFP Advisors Inc lifted its holdings in IDEXX Laboratories by 3.6% in the fourth quarter. IFP Advisors Inc now owns 903 shares of the company’s stock valued at $373,000 after buying an additional 31 shares during the period. Finally, Cape Cod Five Cents Savings Bank lifted its holdings in IDEXX Laboratories by 0.5% in the third quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company’s stock valued at $3,091,000 after buying an additional 32 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Down 1.6 %

IDEXX Laboratories stock opened at $415.87 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm’s fifty day moving average price is $437.07 and its two-hundred day moving average price is $442.90. The firm has a market capitalization of $33.71 billion, a price-to-earnings ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.